Stevens T P, Blennow M, Soll R F
University of Rochester, Dept of Pediatrics (Neonatology), Box 651, 601 Elmwood Ave, Rochester, NY 14642, USA. timothy
Cochrane Database Syst Rev. 2002(2):CD003063. doi: 10.1002/14651858.CD003063.
Both early and prophylactic surfactant replacement therapy compared with later selective surfactant administration reduces mortality and pulmonary complications in ventilated infants with respiratory distress syndrome (RDS). Continuous distending pressure (CDP) has also been shown to improve clinical outcomes in preterm infants with RDS.
To compare two treatment strategies in preterm infants with, or at risk for, RDS: early surfactant administration with brief mechanical ventilation (less than 1 hour) followed by extubation, vs later, selective surfactant administration, continued mechanical ventilation and extubation from low respiratory support. Two populations of infants receiving early surfactant were considered: spontaneously breathing infants with signs of RDS (surfactant administration during evolution of RDS prior to requiring intubation for respiratory failure) and infants at high risk for RDS (prophylactic surfactant administration within 15 minutes after birth).
Searches were made of the Oxford Database of Perinatal trials, MEDLINE (1966-December 2001), CINAHL (1982-December 2001), EMBASE (1980-December 2001), Cochrane Controlled Trials Register (The Cochrane Library, Issue 1, 2002), Pediatric Research (1990-2001), abstracts, expert informants and hand searching. No language restrictions were applied.
Randomized or quasi-randomized controlled clinical trials comparing early surfactant administration with planned brief mechanical ventilation (less than one hour) followed by extubation, vs selective surfactant administration, continued mechanical ventilation and extubation from low respiratory support.
Data were sought regarding effects on incidence of mechanical ventilation (ventilation continued or initiated beyond one hour after surfactant administration), incidence of bronchopulmonary dysplasia (BPD, need for oxygen at 28 days of age), incidence of chronic lung disease (CLD, need for oxygen at 36 weeks' post-conceptional age), mortality (neonatal mortality < 28 days and mortality prior to hospital discharge), duration of mechanical ventilation, duration of hospitalization, time in oxygen, duration of respiratory support (including CPAP and nasal cannula), number of patients receiving surfactant, number of surfactant doses administered per patient, incidence of air leak syndromes (pulmonary interstitial emphysema, pneumothorax), incidence of pulmonary hemorrhage, and other complications of prematurity. Data analyses were performed in accordance with the standards of the Cochrane Neonatal Review Group.
Only one randomized controlled clinical trial met selection criteria and was included in this review (Verder 1994). In this study of infants with signs of RDS, intubation and early surfactant therapy followed by extubation to nasal CPAP (NCPAP) compared with later, selective surfactant administration was associated with a lower incidence of mechanical ventilation (ventilation continuing for one hour or more after surfactant administration in the early surfactant group or initiated for respiratory insufficiency or apnea in either group [RR 0.51, 95% CI 0.32, 0.76]). A larger proportion of infants in the early surfactant group received surfactant than in the selective surfactant group [RR 1.74, 95% CI 1.30, 2.33]. The number of surfactant doses per patient was significantly greater among patients randomized to the early surfactant group [MD 0.51, 95% CI 0.32, 0.70]. Trends towards a decreased incidence of mortality, and a higher rate of patent ductus arteriosus requiring treatment were seen in the early surfactant group. There was no evidence of effect on median time in oxygen, duration of mechanical ventilation, or incidence of BPD (oxygen at 28 days).
REVIEWER'S CONCLUSIONS: Early surfactant replacement therapy with extubation to NCPAP compared with later, selective surfactant replacement and continued mechanical ventilation with extubation from low ventilator support is associated with a reduced need for mechanical ventilation and increased utilization of exogenous surfactant therapy. These conclusions are based on findings from one small randomized clinical trial. Additional randomized trials are needed and are underway.
与后期选择性使用表面活性剂相比,早期和预防性表面活性剂替代疗法可降低呼吸窘迫综合征(RDS)通气婴儿的死亡率和肺部并发症。持续扩张压力(CDP)也已被证明可改善患有RDS的早产儿的临床结局。
比较两种治疗策略用于患有RDS或有RDS风险的早产儿:早期使用表面活性剂并进行短暂机械通气(少于1小时)然后拔管,与后期选择性使用表面活性剂、持续机械通气并从低呼吸支持水平拔管。考虑了两组接受早期表面活性剂治疗的婴儿:有RDS体征的自主呼吸婴儿(在RDS进展期间、因呼吸衰竭需要插管之前给予表面活性剂)和有RDS高风险的婴儿(出生后15分钟内预防性给予表面活性剂)。
检索了牛津围产期试验数据库、MEDLINE(1966年 - 2001年12月)、CINAHL(1982年 - 2001年12月)、EMBASE(1980年 - 2001年12月)、Cochrane对照试验注册库(Cochrane图书馆,2002年第1期)、《儿科研究》(1990年 - 2001年)、摘要、专家信息提供者并进行了手工检索。未设语言限制。
比较早期使用表面活性剂并计划进行短暂机械通气(少于1小时)然后拔管,与选择性使用表面活性剂、持续机械通气并从低呼吸支持水平拔管的随机或半随机对照临床试验。
收集有关以下方面的数据:机械通气发生率(表面活性剂给药后通气持续或开始超过1小时)、支气管肺发育不良(BPD,28日龄时需要吸氧)发生率、慢性肺病(CLD,孕龄36周时需要吸氧)发生率、死亡率(新生儿死亡率<28天及出院前死亡率)、机械通气持续时间、住院时间、吸氧时间、呼吸支持持续时间(包括持续气道正压通气和鼻导管吸氧)、接受表面活性剂治疗的患者数量、每位患者给予的表面活性剂剂量数量、气漏综合征(肺间质气肿、气胸)发生率、肺出血发生率以及其他早产并发症。数据分析按照Cochrane新生儿综述组的标准进行。
仅有一项随机对照临床试验符合选择标准并纳入本综述(Verder 1994)。在这项对有RDS体征婴儿的研究中,与后期选择性使用表面活性剂相比,插管并早期给予表面活性剂治疗然后拔管至鼻持续气道正压通气(NCPAP)与较低的机械通气发生率相关(早期表面活性剂组表面活性剂给药后通气持续1小时或更长时间,或两组中因呼吸功能不全或呼吸暂停开始通气[相对危险度(RR)0.51,95%可信区间(CI)0.32,0.76])。早期表面活性剂组接受表面活性剂治疗的婴儿比例高于选择性表面活性剂组[RR 1.74,95% CI 1.30,2.33]。随机分配至早期表面活性剂组的患者每位给予的表面活性剂剂量显著更多[平均差(MD)0.51,95% CI 0.32, 0.70]。早期表面活性剂组有死亡率降低的趋势,以及更高的需要治疗的动脉导管未闭发生率。没有证据表明对中位吸氧时间、机械通气持续时间或BPD发生率(28日龄时吸氧)有影响。
与后期选择性表面活性剂替代治疗以及持续机械通气并从低通气支持水平拔管相比,早期表面活性剂替代治疗并拔管至NCPAP与机械通气需求减少和外源性表面活性剂治疗利用率增加相关。这些结论基于一项小型随机临床试验的结果。还需要并正在进行更多的随机试验。